doc. MUDr. Daniela Žáčková, Ph.D.

Associate professor, Department of Internal Medicine, Hematology and Oncology

correspondence Address:
Jihlavská 340/20, 625 00 Brno

phone:	+420 532 23 2838, 3603
e‑mail:

social and academic networks:

Basic information

Supervision

Qualifications

Publications

Type

Total number of publications: 222

2022

Komplexní cytogenomická a molekulárně biologická analýza nádorového genomu pacientů s myeloidními malignitami se zaměřením na cílenou analýzu genu MECOM.

BRYJOVÁ Lenka ONDROUŠKOVÁ Eva ČÁBELOVÁ Kateřina ŠMEJKAL Jiří ŠMUHAŘOVÁ Petra KOTAŠKOVÁ Jana MAREČKOVÁ Andrea BOHÚNOVÁ Michaela JEŽÍŠKOVÁ Ivana FOLTA Adam SMITALOVÁ Dagmar DOUBEK Michael WEINBERGEROVÁ Barbora ČERVINEK Libor PANOVSKÁ Anna ŽÁČKOVÁ Daniela JAROŠOVÁ Marie

Conference abstract

Year: 2022, type: Conference abstract
Přídatné cytogenetické abnormality prokázané při diagnóze CML a jejich vliv na prognózu – analýza z databáze INFINITY

ČIČÁTKOVÁ Petra JAROŠOVÁ Marie MAZALOVÁ Monika MAYER Jiří ŽÁČKOVÁ Daniela PAVLÍK Tomáš KLAMOVÁ Hana BĚLOHLÁVKOVÁ Petra STEJSKAL Lukáš FABER Edgar HORŇÁK Tomáš KVETKOVÁ Anežka SEMERÁD Lukáš PROCHÁZKOVÁ Jiřina CMUNT Eduard ČERNÁ Olga RANSDORFOVÁ Šárka

Conference abstract

Year: 2022, type: Conference abstract
Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure

PERUSINI MA. PAGNANO K. PAVLOVSKY C. PAGNANO K. MOIRAGHI B. VARELA AI. BIANCHINI M. MAYER Jiří ŽÁČKOVÁ Daniela KVETKOVÁ Anežka JURČEK Tomáš JEŽÍŠKOVÁ Ivana LOPES ABP. DUARTE G. SOUZA CA. MEDEIROS J. KIM TS. YOO YS. KIM KH. LEE HW. CHANG MH. YI SY. ABELSON S. KIM D.

Conference abstract

Year: 2022, type: Conference abstract
Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia

TAEHYUNG K. ŽÁČKOVÁ Daniela JEŽÍŠKOVÁ Ivana KVETKOVÁ Anežka JURČEK Tomáš YOO YS. LEE H. KIM KH. CHANG MH. YI SY. MEDEIROS J. ABELSON S. KIM D.

Conference abstract

Year: 2022, type: Conference abstract
The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

PERUSINI MA. KIM TS. ŽÁČKOVÁ Daniela PAGNANO K. MAYER Jiří PAVLOVSKY C. JEŽÍŠKOVÁ Ivana KVETKOVÁ Anežka JURČEK Tomáš MOIRAGHI B VARELA AI. BIANCHINI M. LOPES ABP. DUARTE G. YOO YS. SOUZA CA. MEDEIROS J. LEE HW. KIM KH. YI SY. CHANG MH. ABELSON S. KIM DDH.

Conference abstract

Year: 2022, type: Conference abstract

2021

Cévní nežádoucí účinky u pacientů s chronickou myeloidní leukemií při terapii inhibitory tyrozinkináz v každodenní klinické praxi – analýza z databáze INFINITY

ČIČÁTKOVÁ Petra KLAMOVÁ Hana BĚLOHLÁVKOVÁ Petra STEJSKAL Lukáš KŘÍSTKOVÁ Zlatuše BARANOVÁ Jana KVETKOVÁ Anežka HORŇÁK Tomáš SEMERÁD Lukáš PROCHÁZKOVÁ Jiřina MAYER Jiří ŽÁČKOVÁ Daniela

Conference abstract

Year: 2021, type: Conference abstract
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

ŽÁČKOVÁ Daniela KLAMOVA Hana BELOHLAVKOVA Petra STEJSKAL Lukas NEČASOVÁ Tereza SEMERÁD Lukáš WEINBERGEROVÁ Barbora SRBOVA Dana VOGLOVA Jaroslava ČIČÁTKOVÁ Petra ŠUSTKOVÁ Zuzana HORŇÁK Tomáš BARANOVÁ Jana PROCHÁZKOVÁ Jiřina MAYER Jiří

Article in Periodical

LEUKEMIA & LYMPHOMA, year: 2021, volume: 62, edition: 1, DOI
Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).

ŽÁČKOVÁ Daniela FABER Edgar STEJSKAL L. KARAS M. BĚLOHLÁVKOVÁ P. KLAMOVÁ H. ČERNÁ O. CMUNT Eduard ČIČÁTKOVÁ Petra SEMERÁD Lukáš HORŇÁK Tomáš KVETKOVÁ Anežka PROCHÁZKOVÁ Jiřina RYCHLÍČKOVÁ Jitka ŠTĚPÁNOVÁ Radka SVOBODNÍK Adam MACHOVÁ POLÁKOVÁ Kateřina JEŽÍŠKOVÁ Ivana JURČEK Tomáš BORSKÝ Marek WIEWIORKA Ondřej MAYER Jiří

Conference abstract

Year: 2021, type: Conference abstract
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients

FOLTA Adam JURCEK Tomas KUBESOVA Blanka ŽÁČKOVÁ Daniela SEMERÁD Lukáš MAYER Jiří JEŽÍŠKOVÁ Ivana

Article in Periodical

LEUKEMIA & LYMPHOMA, year: 2021, volume: 62, edition: 5, DOI
Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

ŽÁČKOVÁ Daniela FABER Edgar STEJSKAL L. KARAS M. BĚLOHLÁVKOVÁ Petra KLAMOVÁ H. ČERNÁ O. CMUNT Eduard ČIČÁTKOVÁ Petra SEMERÁD Lukáš HORŇÁK Tomáš KVETKOVÁ Anežka PROCHÁZKOVÁ Jiřina RYCHLÍČKOVÁ Jitka ŠTĚPÁNOVÁ Radka SVOBODNÍK Adam MACHOVÁ POLÁKOVÁ Kateřina JEŽÍŠKOVÁ Ivana JURČEK Tomáš BORSKÝ Marek WIEWIORKA Ondřej DEMLOVÁ Regina MAYER Jiří

Conference abstract

Year: 2021, type: Conference abstract

Projects

Teaching

10 reasons why you will fall in love with MU

Ask our ambassador

Read about research at MU

doc. MUDr. Daniela Žáčková, Ph.D.

2022

Komplexní cytogenomická a molekulárně biologická analýza nádorového genomu pacientů s myeloidními malignitami se zaměřením na cílenou analýzu genu MECOM.

Přídatné cytogenetické abnormality prokázané při diagnóze CML a jejich vliv na prognózu – analýza z databáze INFINITY

Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure

Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

2021

Cévní nežádoucí účinky u pacientů s chronickou myeloidní leukemií při terapii inhibitory tyrozinkináz v každodenní klinické praxi – analýza z databáze INFINITY

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).

Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients

Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.